NCI-TARGET Clinical Performance(Medical Statistics Report of Human Testing)

  1. First, Physiological and physical response by oral for half month(Sampling 150 persons)
    1. A. cancer patient's feeling
      1. Significantly improved (92.5%)
      2. Slightly improved (6.5%)
      3. No feeling (1%)
      4. Feel bad (0%)
      5. Obviously bad (0%)
    2. Non-cancer patient's feeling
      1. Significantly improved (55%)
      2. Slightly improved (30%)
      3. No feeling (14%)
      4. Feel bad (1%)
      5. Obviously bad (0%)
  2. Second, Result of Cancer chemotherapy patients by oral for half month White blood cells (immune changes) (sampling 150 persons)
    1. Significantly improved (84.5%)
    2. Slight improved (14%)
    3. No change (1.5%)
    4. Relatively reduced (0%)
    5. Significantly reduced (0%)
  3. Third, Tumor index change of cancer chemotherapy patients by oral within three months (sampling 60 persons) :
    1. Decreased (96.5%)
    2. Unchanged (3.5%)
    3. Increased(0%).


Clinical Performance of Cancer Patients

Breast cancer - nine cases (B101~109)

Colorectal cancer - nine cases (C101~109)

Liver cancer - nine cases (H101~109)

Lung cancer and lymphoma - five cases(L101~105)

Most recent news
In 2004, NCI-TARGET / Treatment has taken out the medical patent of "Anti-cancer Agent" (Anti-tumor Composition) in USA. Its non-toxic anti-cancer effects (LD50 = 4000mg) have been proved by the animal test models separately from the cancer clinical trial and the anti-cancer treatment, and it can be used for clinical purposes or human consumptions. In addition, it is effective for liver function (GOT / AST, GPT / ALT index), renal (BUN, Creatinine index and uric acid gout), long-term stomach pain or hematopoietic function (platelet / white blood cells) and gynecological fields. It is a special medical technology in the world.
 
NCI-TARGET Efficacy Mechanism
NCI-TARGET Clinical Performance
Improve Your Body
Test Result for Cancer
Who and How Use It
 
© 2010 NCI target | All right reserved